Effects of Chimeric Decoy Oligodeoxynucleotide in the Regulation of Transcription Factors NF-κB and Sp1 in an Animal Model of Atherosclerosis

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 4, 2013, Pages 236-243

  Lee, Woo Ram ^a   Kim, Kyung Hyun ^a   An, Hyun Jin ^a   Park, Yoon Yub ^a   Kim, Kee Sik ^a   Lee, Chong Kee ^a   Min, Bo Kyung ^a   Park, Kwan Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC DECOY OLIGODEOXYNUCLEOTIDE; CHOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CHIMERA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; TAIL;

ANIMALS; ATHEROSCLEROSIS; BINDING SITES; CHOLESTEROL; CYTOKINES; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; SP1 TRANSCRIPTION FACTOR; TIME FACTORS;

ANIMALIA; MUS;

EID: 84875061569     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12029     Document Type: Article

References (42)

1. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
3. Getz GS. Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 2005;46:1-10.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
6. Thurberg BL, Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998;9:387-96.
7. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997;65:111-37.
8. Kim SJ, Park JH, Kim KH, Lee WR, Lee S, Kwon OC et al. Effect of NF-kappaB decoy oligodeoxynucleotide on LPS/high-fat diet-induced atherosclerosis in an animal model. Basic Clin Pharmacol Toxicol 2010;107:925-30.
9. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2394-400.
10. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996;16:1000-6.
11. Olofsson PS, Sheikine Y, Jatta K, Ghaderi M, Samnegard A, Eriksson P et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 2009;73:1531-6.
12. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005;180:11-7.
13. Zhang L, Peppel K, Sivashanmugam P, Orman ES, Brian L, Exum ST et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1087-94.
14. Iademarco MF, McQuillan JJ, Dean DC. Vascular cell adhesion molecule 1: contrasting transcriptional control mechanisms in muscle and endothelium. Proc Natl Acad Sci U S A 1993;90:3943-7.
15. Neish AS, Khachigian LM, Park A, Baichwal VR, Collins T. Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J Biol Chem 1995;270:28903-9.
16. Irvine SA, Foka P, Rogers SA, Mead JR, Ramji DP. A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophages. Nucleic Acids Res 2005;33:1423-34.
17. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9.
18. Magae J, Munemura K, Ichikawa C, Osada K, Hanada T, Tsuji RF et al. Effects of microbial products on glucose consumption and morphology of macrophages. Biosci Biotechnol Biochem 1993;57:1628-31.
19. Kim KH, Park JH, Lee WR, Park JS, Kim HC, Park KK. Inhibitory effects of chimeric decoy oligodeoxynucleotide in the regulation of transcription factors NF-κB and Sp1 in an animal model of liver cirrhosis. J Life Sci 2009;19:1360-7.
20. Miyake T, Aoki M, Morishita R. Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model. Cardiovasc Res 2008;79:706-14.
21. Miyake T, Aoki M, Osako MK, Shimamura M, Nakagami H, Morishita R. Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor kappaB and ets prevents abdominal aortic aneurysm in rat model. Mol Ther 2011;19:181-7.
22. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98.
23. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005;114:278-83.
24. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
25. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
26. Xu S, Liu AC, Gotlieb AI. Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-beta. Cardiovasc Pathol 2010;19:236-47.
27. Feaver RE, Gelfand BD, Wang C, Schwartz MA, Blackman BR. Atheroprone hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation. Circ Res 2010;106:1703-11.
28. Morishita R, Aoki M, Kaneda Y. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs? Curr Drug Targets 2000;1:15-23.
29. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-8.
30. Kim KH, Lee ES, Cha SH, Park JH, Park JS, Chang YC et al. Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy. Exp Mol Pathol 2009;86:114-20.
31. Kum YS, Kim KH, Park TI, Suh IS, Oh HK, Cho CH et al. Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis. Biochem Biophys Res Commun 2007;363:368-74.
32. Miyake T, Aoki M, Nakashima H, Kawasaki T, Oishi M, Kataoka K et al. Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther 2006;13:695-704.
33. Kubo T, Kinjyo N, Ikezawa A, Kambe T, Fukumori R. Sp1 decoy oligodeoxynucleotide decreases angiotensin receptor expression and blood pressure in spontaneously hypertensive rats. Brain Res 2003;992:1-8.
34. Dillard A, Matthan NR, Lichtenstein AH. Use of hamster as a model to study diet-induced atherosclerosis. Nutr Metab (Lond). 2010;7:89.
35. Nishina PM, Lowe S, Verstuyft J, Naggert JK, Kuypers FA, Paigen B. Effects of dietary fats from animal and plant sources on diet-induced fatty streak lesions in C57BL/6J mice. J Lipid Res 1993;34:1413-22.
36. Kim SJ, Park JH, Kim KH, Lee WR, Kim KS, Park KK. Melittin inhibits atherosclerosis in LPS/high-fat treated mice through atheroprotective actions. J Atheroscler Thromb 2011;18:1117-26.
37. Westerterp M, Berbee JF, Pires NM, van Mierlo GJ, Kleemann R, Romijn JA et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007;116:2173-81.
38. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001;104:914-20.
39. Lv S, Fan R, Du Y, Hou M, Tang Z, Ling W et al. Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. Eur J Nutr 2009;48:205-12.
40. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001;104:2638-40.
41. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:E83-8.
42. Chanet A, Milenkovic D, Deval C, Potier M, Constans J, Mazur A et al. Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. J Nutr Biochem 2011;23:469-77.